BPC-157 Cycle: Duration, and Where It Comes From
The durations get quoted precisely, which is the tell. Precision without a citation is a convention that has been repeated until it sounds like data.
BPC-157 cycle lengths get quoted with the confidence of a dosing chart, but no published study has established one for people and no regulator has reviewed one. The durations circulating are conventions. They have been repeated often enough to sound like findings, and tracing them backwards is more useful than comparing them against each other.
Where the order actually gets placed
Ascension Peptides, BPC-157
US-based, with no batch certificate published for this product. Enter the code on the payment step and either option halves before you confirm.
The Wolverine Stack is BPC-157 10 mg combined with TB-500 10 mg in one vial, so its per-mg figure spans both compounds. Quantity tiers take 3%, 5% or 10% off the list price; free shipping starts at $250.
- Two batch certificates per lot
- Shipping free over $250
- Out the door same day if you order before 2pm CST
Everything here is research material for laboratory use, not for human consumption. Affiliate links, so we may earn a commission at no cost to you. Prices last checked August 19, 2026.
Why a BPC-157 cycle has no established duration
A duration becomes established through a specific process. A trial fixes a treatment period in advance, measures outcomes at defined points, and reports whether the period was sufficient. Regulators then review that evidence and an approved duration appears on a label.
None of those steps has been completed here. BPC-157 has no marketing authorisation from the FDA, the EMA or the MHRA, so there is no label, no approved duration and no authority that has evaluated one. It is sold as a research chemical.
That leaves a gap, and gaps in this space fill themselves. The durations that fill this one arrived from other places entirely.
Where the idea of a cycle came from in the first place
The word cycle is borrowed. It comes from anabolic steroid practice, where on and off periods developed around a genuine physiological rationale: suppression of the body's own hormone production, and a need for recovery between periods of use.
That rationale is specific to how those compounds work. Transplanting the vocabulary to a peptide fragment does not transplant the reasoning. Whether a cycle structure makes any sense for this compound is an open question, and it is open because nobody has published the human work that would answer it.
A second source is the general culture of supplement scheduling, where fixed blocks of weeks are conventional. Conventions of that kind are usually inherited rather than derived. They persist because they sound orderly, and orderliness is easy to mistake for evidence.
The precision is itself a signal. Claims tend to get more specific as they are repeated, not less, because a rounded number sounds vague and a precise one sounds researched. Nothing is added between repetitions except confidence. When a figure is quoted to the day and no source is attached anywhere in the chain, the specificity is a stylistic property rather than a measured one.
A third source is inference from the animal literature. This one at least starts from published work, but the inference involves several unstated jumps, and it is worth laying out where each jump happens.
| Element of a typical cycle claim | Stated source | What published work supports it | Organism |
|---|---|---|---|
| A fixed number of weeks | Usually none given | No published human duration study | Not applicable |
| An amount per day | Often converted from animal work | Animal dosing expressed per kilogram of body weight | Rat |
| An off period | Steroid practice | No published rationale for this compound | Not applicable |
| Repeating the cycle | Convention | No published repeat exposure data in people | Not applicable |
| A route of administration | Convenience and convention | Multiple routes appear in animal work, none validated for people | Rat |
| Expected timeline of effect | Personal reports | No published human efficacy results | Human, uncontrolled |
Every row that names an organism names a rat. Every row without one has no study behind it at all. That is the whole diagnosis of a typical cycle claim in one column: the parts that came from research came from animals, and the parts that shape the schedule came from nowhere in particular.
What duration actually meant in the animal studies
The rat work does specify treatment periods, so there is something real underneath the inference. The problem is what those periods were anchored to.
In these designs, the injury is created by the researchers at a recorded moment. Administration begins at a fixed interval after that moment. It continues for a period chosen around the healing window of that particular model in that particular tissue, and then the tissue is collected and measured. The duration exists to answer a question about the model, not to recommend anything.
Three features of that make it non transferable. The start point is a scheduled injury, which no person outside a laboratory has. The end point is tissue collection, which is not available in a living person. And the length was selected for the biology of a rat tendon or a rat gut lesion, which is not a stand in for human healing.
There is also the matter of what was compared. The finding in those studies is the difference between treated animals and untreated animals with the same injury. Untreated animals improve too. A duration that produced a measurable difference in that comparison tells you about the comparison, not about how long a person should do anything.
What the registered human trials will actually define
Human trials on this compound are registered, which makes the claim that none exist inaccurate. Two are citable. NCT07803250 is a Phase 1 study with a planned enrolment of 30 participants in recovery after rotator cuff repair, listed as not yet recruiting. NCT02637284 is a Phase 1 study of 42 participants covering safety and pharmacokinetics, with status listed as unknown.
None has published efficacy results. Both halves belong together: registered human work exists, and it has not reported.
What trials of this kind establish, when they report, is exactly the thing missing here. A treatment period fixed in advance rather than chosen afterwards. Outcomes measured at predefined points. A control arm, so that the passage of time is accounted for. Assessment by people who do not know which arm a participant was in. That combination is what converts a duration from a habit into a finding.
Pharmacokinetic work matters here too, because how long a compound persists in the body is part of what any sensible schedule would be built on. That is the sort of question a Phase 1 study addresses, and its results have not been published for this compound.
Duration and safety are also coupled in a way that cycle discussions tend to separate. A longer period is not only more of a possible effect, it is more exposure, and the harms that show up with extended use are a different category from the ones that show up immediately. Nothing has been published on either for this compound in people, so a longer schedule is not a cautious version of a shorter one. Both sit outside the evidence, and the longer one sits further outside it.
Reading a cycle claim, in order
Work through a claim in this sequence and it usually comes apart at a predictable point.
Ask where the duration came from. If no source is named, the answer is convention, and conventions have no evidence behind them by definition.
Ask what organism produced the underlying number, if one exists. Rat is the honest answer for most of this literature, and a rat derived figure should be presented as an extrapolation rather than a dose.
Ask whether an off period has any stated rationale beyond habit. For steroid practice there is one. For this compound, none has been published.
Ask what outcome the cycle is supposed to produce, and whether that outcome is measurable by the person following it. Tissue structure is not.
Ask who benefits from the schedule existing. A vendor selling by the vial has an interest in a defined quantity being consumed over a defined period, and that interest does not require anyone to be dishonest for it to shape what gets published.
Related reading on this compound: what the published protocols ran, why before and after images do not settle it, what BPC-157 actually is.